Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

ACTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes in critical care settings, today provided a corporate update highlighting progress achieved during the first quarter of 2026 and recent operational developments related to its Symphony™ near-patient diagnostic platform.

07.04.2026

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

ACTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on rapid, near-patient testing, today announced the successful enrollment of 624 patients in its ongoing SYMON-II Trial, a pivotal clinical study evaluating the Company's Symphony™ platform for interleukin-6 (IL-6) testing in critical care settings to determine patient acuity for sepsis triage and monitoring.

12.03.2026

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented. New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented.

11.03.2026

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics

NEWPORT BEACH, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- NorthStrive Fund II LP (“NorthStrive Fund”), a subsidiary of NorthStrive Companies Inc., today issued an open letter to the Board of Directors and shareholders of Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”) recommending the Board evaluate a strategic opportunity that NorthStrive believes could significantly enhance long-term shareholder value.

Bluejay Diagnostics, Inc. (BJDX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Bluejay Diagnostics, Inc. (BJDX)

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics

Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026

Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production

Videolar

No Data

Press-relizlar

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics

Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026

Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production

Videolar

No Data

Press-relizlar

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics

Search stocks

Bluejay Diagnostics, Inc. (BJDX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Bluejay Diagnostics, Inc. (BJDX)

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics

Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026

Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production

Videolar

No Data

Press-relizlar

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics

Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026

Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production

Videolar

No Data

Press-relizlar

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics